(Q24245404)

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Treatment of multiple sclerosis with mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

An open-trial evaluation of mitoxantrone in the treatment of progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Evaluation of mitoxantrone cardiac toxicity by nuclear angiography and endomyocardial biopsy: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Molecular and biochemical pharmacology of mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Linking structural, metabolic and functional changes in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Decrease in heart ventricular ejection fraction during multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Interferon in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Mitoxantrone (novantrone): a review of experimental and early clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-1b in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Suppression of demyelination by mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

21 January 2018

Dexrazoxane (ICRF-187).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

Noninvasive Assessment of Mitoxantrone Cardiotoxicity in Relapsing Remitting Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Secondary leukemias induced by topoisomerase-targeted drugs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell-mediated myelin-directed autoimmunity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002127.PUB2

7 January 2021